Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry)
- PMID: 16377276
- DOI: 10.1016/j.amjcard.2005.07.122
Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry)
Abstract
Enhanced external counterpulsation (EECP) is a noninvasive circulatory assist device that has recently emerged as a treatment option for refractory angina in left ventricular (LV) dysfunction. This 2-year cohort study describes the long-term follow-up of patients who had severe LV dysfunction that was treated with EECP for angina pectoris and reports clinical outcomes, event-free survival rates, and the incidence of repeat EECP. This study included 363 patients who had refractory angina and LV ejection fraction < or =35%. Most patients reported quality of life as poor. After completion of treatment, there was a significant decrease in severity of angina class (p < 0.001), and 72% improved from severe angina to no angina or mild angina. Fifty-two percent of patients discontinued nitroglycerin use. Quality of life improved substantially. At 2 years this decrease in angina was maintained in 55% of patients. The 2-year survival rate was 83%, and the major adverse cardiovascular event-free survival rate was 70%. Forty-three percent had no reported cardiac hospitalization; 81% had no reported congestive heart failure events. Repeat EECP was performed in 20% of these patients. The only significant independent predictor of repeat EECP in a proportional hazard model was failure to complete the first EECP treatment course (hazard ratio 2.9, 95% confidence interval 1.7 to 4.9). Improvements in angina symptoms and quality of life were maintained at 2 years. In conclusion, for patients who have high-risk LV dysfunction, EECP offers an effective, durable therapeutic approach for refractory angina. Decreased angina and improvement in quality of life were maintained at 2 years, with modest repeat EECP and low major cardiovascular event rates.
Similar articles
-
Residual high-grade angina after enhanced external counterpulsation therapy.Cardiovasc Revasc Med. 2007 Jul-Sep;8(3):161-5. doi: 10.1016/j.carrev.2006.12.003. Cardiovasc Revasc Med. 2007. PMID: 17765644
-
Frequency and efficacy of repeat enhanced external counterpulsation for stable angina pectoris (from the International EECP Patient Registry).Am J Cardiol. 2005 Feb 1;95(3):394-7. doi: 10.1016/j.amjcard.2004.09.041. Am J Cardiol. 2005. PMID: 15670552
-
The efficacy and safety of enhanced external counterpulsation in patients with peripheral arterial disease.Vasc Med. 2010 Feb;15(1):15-20. doi: 10.1177/1358863X09106549. Epub 2009 Oct 19. Vasc Med. 2010. PMID: 19841026
-
Enhanced external counterpulsation and future directions: step beyond medical management for patients with angina and heart failure.J Am Coll Cardiol. 2007 Oct 16;50(16):1523-31. doi: 10.1016/j.jacc.2007.07.024. Epub 2007 Oct 1. J Am Coll Cardiol. 2007. PMID: 17936150 Review.
-
Enhanced external counterpulsation: an innovative physical therapy for refractory angina.PM R. 2009 Mar;1(3):268-76. doi: 10.1016/j.pmrj.2008.12.002. PM R. 2009. PMID: 19627906 Review.
Cited by
-
Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials.Quant Imaging Med Surg. 2024 Feb 1;14(2):1451-1465. doi: 10.21037/qims-23-1029. Epub 2024 Jan 9. Quant Imaging Med Surg. 2024. PMID: 38415135 Free PMC article.
-
Enhanced External Counterpulsation for Management of Postacute Sequelae of SARS-CoV-2 Associated Microvascular Angina and Fatigue: An Interventional Pilot Study.Cardiol Res Pract. 2023 Dec 27;2023:6687803. doi: 10.1155/2023/6687803. eCollection 2023. Cardiol Res Pract. 2023. PMID: 38179014 Free PMC article.
-
Refractory angina pectoris: a 20-year (2003-2022) bibliometric analysis.Front Cardiovasc Med. 2023 Aug 24;10:1228201. doi: 10.3389/fcvm.2023.1228201. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37692051 Free PMC article.
-
The Effect of EECP on Ischemic Heart Failure: a Systematic Review.Curr Cardiol Rep. 2023 Oct;25(10):1291-1298. doi: 10.1007/s11886-023-01943-1. Epub 2023 Aug 29. Curr Cardiol Rep. 2023. PMID: 37642929 Free PMC article. Review.
-
External Counterpulsation Improves Angiogenesis by Preserving Vascular Endothelial Growth Factor-A and Vascular Endothelial Growth Factor Receptor-2 but Not Regulating MicroRNA-92a Expression in Patients With Refractory Angina.Front Cardiovasc Med. 2021 Oct 25;8:761112. doi: 10.3389/fcvm.2021.761112. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34760951 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
